Tharimmune, Inc. | WebDisclosure

Switch to English

8301	Sociétés
115073	Mots-clés
55422	Articles
62513	Communiqués

Accueil
Sociétés
Tharimmune, Inc.

BRÈVE

publiée le 30/04/2024 à 14:36, il y a 6 mois 21 jours

Tharimmune to Engage Investors at Two Major Conferences in May

Biotechnology Investor Conferences Investor Engagement Tharimmune Inflammation And Immunology
BRÈVE

publiée le 30/04/2024 à 14:36, il y a 6 mois 21 jours

Tharimmune va impliquer les investisseurs lors de deux conférences majeures en mai

Biotechnologie Conférences Investisseurs Engagement Des Investisseurs Tharimmune Inflammation Et Immunologie
COMMUNIQUÉ DE PRESSE

publié le 30/04/2024 à 14:31, il y a 6 mois 21 jours

Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune to present at investor conferences in May 2024, showcasing developments in inflammation & immunology therapies. CEO to participate in Planet MicroCap Showcase: VEGAS 2024 & EF Hutton Annual Global Conference

Investor Conferences Tharimmune Inflammation Immunology Therapeutic Candidates
BRÈVE

publiée le 23/04/2024 à 13:36, il y a 6 mois 28 jours

Tharimmune obtient le droit de développer des conjugués anticorps-médicaments innovants

Tharimmune, Inc. Anticorps HER2/HER3 Conjugués Anticorps-médicament (ADC) Immunologie Du Cancer Nouvelles Thérapies
BRÈVE

publiée le 23/04/2024 à 13:36, il y a 6 mois 28 jours

Tharimmune Secures Rights to Develop Innovative Antibody Drug Conjugates

Tharimmune, Inc. HER2/HER3 Antibodies Antibody Drug Conjugates (ADCs) Cancer Immunology Novel Therapeutics
COMMUNIQUÉ DE PRESSE

publié le 23/04/2024 à 13:31, il y a 6 mois 28 jours

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Tharimmune, Inc. obtains rights from Washington University to develop human HER2 antibodies, expanding its pipeline of novel tunable antibodies for HER2 & HER3

Biotechnology Tharimmune Inc. Washington University HER2 Antibodies Novel Antibodies
COMMUNIQUÉ DE PRESSE

publié le 20/02/2024 à 14:01, il y a 9 mois 1 jour

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings

Tharimmune Inc. TH104 Phase 1 Trial Chronic Pruritus Primary Biliary Cholangitis
BRÈVE

publiée le 20/02/2024 à 14:01, il y a 9 mois 1 jour

Tharimmune announces positive Phase 1 results for TH104 and funding until 2025

Biotechnology Phase 1 Clinical Trial Funding TH104 Primary Biliary Cholangitis
BRÈVE

publiée le 20/02/2024 à 14:01, il y a 9 mois 1 jour

Tharimmune annonce les résultats positifs de la Phase 1 pour TH104 et le financement jusqu'en 2025

Biotechnologie Financement TH104 Essai Clinique De Phase 1 Cholangite Biliaire Primitive
COMMUNIQUÉ DE PRESSE

publié le 05/02/2024 à 14:30, il y a 9 mois 16 jours

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts

Phase 1 Clinical Trial Tharimmune Inc. TH104 Liver-related Conditions Pruritogenic Inflammatory Conditions

Les Echos

Publié le 21/11/2024 à 06:58, il y a 12 heures 12 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 12 heures 12 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 12 heures 12 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 23 heures 2 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 23 heures 50 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 17:35, il y a 1 heure 35 minutes

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Publié le 21/11/2024 à 17:30, il y a 1 heure 40 minutes

SimpliGov and Proof Partner to Offer Online Notarization
Publié le 21/11/2024 à 16:30, il y a 2 heures 40 minutes

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Publié le 21/11/2024 à 16:01, il y a 3 heures 9 minutes

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Publié le 21/11/2024 à 16:00, il y a 3 heures 10 minutes

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 18:36, il y a 34 minutes

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:58, il y a 1 heure 11 minutes

Funding Circle Plc: POS-Transaction in Own Shares
Publié le 21/11/2024 à 17:51, il y a 1 heure 18 minutes

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 1 heure 18 minutes

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 1 heure 18 minutes

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.